1. Home
  2. HYI vs FHTX Comparison

HYI vs FHTX Comparison

Compare HYI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset High Yield Defined Opportunity Fund Inc.

HYI

Western Asset High Yield Defined Opportunity Fund Inc.

SELL

Current Price

$9.24

Market Cap

135.2M

Sector

Finance

ML Signal

SELL

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

SELL

Current Price

$1.73

Market Cap

111.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HYI
FHTX
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.2M
111.1M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
HYI
FHTX
Price
$9.24
$1.73
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $4.17
AVG Volume (30 Days)
96.8K
★ 685.8K
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 9.59%
N/A
EPS Growth
N/A
★ 25.32
EPS
N/A
★ 0.43
Revenue
N/A
★ $30,909,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$4.15
Revenue Growth
N/A
★ 36.75
52 Week Low
$9.42
$1.73
52 Week High
$11.26
$7.61

Technical Indicators

Market Signals
Indicator
HYI
FHTX
Relative Strength Index (RSI) 28.03 31.88
Support Level N/A N/A
Resistance Level $10.66 $2.28
Average True Range (ATR) 0.14 0.17
MACD -0.03 0.02
Stochastic Oscillator 5.69 6.44

Price Performance

Historical Comparison
HYI
FHTX

About HYI Western Asset High Yield Defined Opportunity Fund Inc.

Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Share on Social Networks: